Healthcare resource allocation for rare diseases: an exploratory survey of Swiss citizens’ preferences
The results suggest that while high treatment costs do pose challenges, they are often secondary to the perceived benefits of treatment; Swiss citizens prioritise treatment effectiveness and quality-of-life improvements over rarity or treatment cost when considering funding decisions.
Authors
- Olivier Devuyst (ORCID: https://orcid.org/0000-0003-3744-4767)
- Giovanni Spitale (ORCID: https://orcid.org/0000-0002-6812-0979)
- Matthias R. Baumgartner (ORCID: https://orcid.org/0000-0002-9270-0826)
- Brigitte Tag
- Federico Germani (ORCID: https://orcid.org/0000-0002-5604-0437)
- Claire Fischer
- Nikola Biller‐Andorno (ORCID: https://orcid.org/0000-0001-7661-1324)
- Janine Reichenbach (ORCID: https://orcid.org/0000-0002-9008-1312)
Institutions
- University of Zurich (CH)
- Swiss Institute for Regenerative Medicine (CH)
- University Hospital of Zurich (CH)
- University Children's Hospital Zurich (CH)
Publication Details
- Journal
- Swiss Medical Weekly
- Published
- 2025-09-18
- DOI
- https://doi.org/10.57187/s.4243
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00